AstraZeneca Group (AZN)
AstraZeneca Group Market Cap: 53.22B
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
AZN Market Cap Rankings
| Overall | 97th percentile | 97 of 4650 |
| Sector | 97th percentile | 12 of 526 in Healthcare |
| Industry | 66th percentile | 9 of 27 in Drug Manufacturers - Major |
AZN Market Cap Range, Past 5 Years
| Minimum | 52.25B | Mar 2009 |
| Maximum | 81.93B | Jun 2007 |
| Average | 64.23B |
About Market Capitalization
Market Capitalization (Market Cap) is a measurement of business value based on share price and number of shares outstanding. It generally represents the market's view of a company's stock value and is a determining factor in stock valuation.
For example, if a company has 1.5 million shares outstanding at a share price of $25, its market cap is $37.5 million (1.5 million x $25). Companies can be categorized based upon the size of their market capitalization.
There are five basic groups: mega-cap (market cap over $200B), large-cap ($10B–$200B), mid-cap ($2B–$10B), small-cap ($300M–$2B), and micro-cap ($50M-$300M). Market cap is not always an accurate indication of value because it does not account for debt and other factors.
Learn More
You may also be interested in these AZN related companies
AZN News
$AZN stop at 40 on 1/3. Have owned a ton of it since early '10. Cost basis ~46 (not inc. divies)
about a day ago by WallStreetBean
about a day ago by WallStreetBean
$AZN “no longer operating in isolation as a pharmaceutical organization.” http://stks.co/3nwQ
about 11 days ago by WallStreetBean
about 11 days ago by WallStreetBean
AstraZeneca (AZN) Says SYMBICORT Shows Similar Safety Profile to Budesonide in Certain Asthma Patient Groups
May 10, 9:02AM Street Insider
May 10, 9:02AM Street Insider
UPDATE - Canaccord Genuity Downgraded Ardea Biosciences (RDEA) To 'Hold'; Q1 Is Non-Event In Light Of Acquisition By AZN
May 08, 9:14AM Street Insider
May 08, 9:14AM Street Insider
Huf Post: Two Drugs Harness Immune System To Fight Cancer. http://stks.co/3iDa $DNDN $BMY $AZN $ONTY $GSK
about 17 days ago by abubnic
about 17 days ago by abubnic
$AMRN U.K.'s second-biggest drugmaker, pharmaceutical giant $AZN, based in London is sniffing around Ireland's small biotech $AMRN
about 20 days ago by JasonMilano8
about 20 days ago by JasonMilano8
Biotech targets fight back as Big Pharma circles. $GSK $BMY $PFE $HGSI $AMLN $ONXX $ILMN $AZN http://stks.co/3dnZ
about 22 days ago by abubnic
about 22 days ago by abubnic
News related to $AZN, currently +0.3% since open: 'Impax Labs falls on weak sales, new FDA warning' http://stks.co/3bhx
about 23 days ago by TradeBot
about 23 days ago by TradeBot
what kinda drug is that? RT @JNapodano $AZN reported $16M in sales of Vimovo - not great, but still higher than consensus. $POZN.
about 24 days ago by WallStreetBean
about 24 days ago by WallStreetBean
Morning News: April 26, 2012 | via @EddyElfenbein http://stks.co/3Wht $FED $DB $NDX $AAPL $CAT $AZN
about 28 days ago by STNet
about 28 days ago by STNet
$AZN trouble in paradise: AstraZeneca CEO to step down as Q1 profit plunges http://stks.co/3WZ3 (holding)
about 28 days ago by WallStreetBean
about 28 days ago by WallStreetBean
News related to $AZN: 'AstraZeneca CEO to step down as Q1 profit plunges' http://stks.co/3WIC
about 28 days ago by TradeBot
about 28 days ago by TradeBot
@taketheplunge $AMRN $AZN has been linked to every biotech on the market in the last 3 months. $AZN could buy...
about 29 days ago by jackofalltrade
about 29 days ago by jackofalltrade
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| AZN | 41.18 | +0.12 | +0.29% | 53.06B |
| AZK | 4.59 | +0.03 | +0.66% | 743.87M |
| AXS | 33.62 | -0.02 | -0.06% | 4.367B |
| AVT | 30.64 | +0.04 | +0.13% | 4.439B |
| AVK | 15.25 | +0.03 | +0.20% | |
| AVCA | 5.98 | -0.03 | -0.50% | 34.98M |
| AVA | 25.46 | +0.40 | +1.58% | 1.468B |
| AU | 36.41 | -0.15 | -0.41% | 14.08B |
| ATVI | 12.11 | -0.22 | -1.78% | 13.84B |
| ATV | 3.80 | -0.32 | -7.76% | 113.58M |
